Clinical Trial Update: Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study of lenalidomide plus rituximab in previously untreated indolent non-Hodgkin lymphoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: University of California, Davis | Conditions: Non Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2025-11-21